Exact Sciences Announces Contract with Anthem BlueCross of California

Expanding Cologuard's In-Network Coverage Supports Continued Growth in 2016

MADISON, Wis. , Jan. 11, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is now covered as an in-network service for more than 4.5 million enrollees of Anthem BlueCross of California , which is part of the second-largest commercial health insurer in the United States .

Read More

Topics: Investor Relations

New Modeling Supports Using Cologuard® Every Three Years

Archimedes model used to conduct screening study in a virtual population of 200,000

MADISON, Wis. , Jan. 11, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced the publication of new modeling data in the peer-reviewed journal Clinical Colorectal Cancer that supports a three-year testing interval for Cologuard (sDNA), the company's FDA -approved, non-invasive, stool-DNA colorectal cancer screening test.

Read More

Topics: Exact Sciences News

Exact Sciences Announces Preliminary Fourth Quarter and Full Year 2015 Results

104,000 Cologuard® tests completed with compliance rate exceeding 70 percent during launch year

MADISON, Wis. , Jan.11, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company completed approximately 38,000 Cologuard tests during the fourth quarter ended Dec. 31, 2015 , generating approximately $14.0 million to $14.5 million in revenue. For the full year 2015, the company expects revenue to be approximately $39.0 million to $39.5 million , the result of completing approximately 104,000 Cologuard tests during its first full year of commercialization. Exact Sciences has not completed preparation of its financial statements for the quarter and full year. These revenue estimates are based on preliminary, unaudited data.

Read More

Cologuard(R) Growth Trajectory Increases to 34,000 Completed Tests, Generates $12.6M in Revenue in Third Quarter 2015

 

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq:EXAS) today announced that the company continued its strong performance during the third quarter ended Sept. 30, 2015, completing 34,000 Cologuard tests, an increase of 60 percent from the second quarter, which resulted in $12.6 million in revenues. The cumulative number of ordering physicians grew to 21,000 during the quarter, an increase of 42 percent.

Read More

Topics: Investor Relations